"We are developing a program of work to support additional indications for Penthrox®. Our longer term ambition is to extend the use of Penthrox® into:
a. post-operative breakthrough pain;
b. breakthrough cancer pain;
c. repeat use scenarios; and ultimately
d. home use."
Ann: Annual Report to shareholders-MVP.AX, page-2
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
47.0¢ |
Change
-0.005(1.05%) |
Mkt cap ! $40.56M | |||
| Open | High | Low | Value | Volume |
| 47.5¢ | 48.5¢ | 47.0¢ | $12.31K | 25.90K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 6111 | 47.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 49.0¢ | 2500 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| MVP (ASX) Chart |